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Abstract
Background: Around 1% of human proteins are predicted to contain a disordered and low complexity prion-like domain
(PrLD). Mutations in PrLDs have been shown promote a transition towards an aggregation-prone state in several diseases.
Results: Recently, we have shown that an algorithm that considers the effects of mutations on PrLDs composition,
as well as on localized amyloid propensity can predict the impact of these amino acid changes on protein
intracellular aggregation. In this application note, we implement this concept into the AMYCO web server, a refined
algorithm that forecasts the influence of amino acid changes in prion-like proteins aggregation propensity better
than state-of-the-art predictors.
Conclusions: The AMYCO web server allows for a fast and automated evaluation of the effect of mutations on the
aggregation properties of prion-like proteins. This might uncover novel disease-linked amino acid changes in the
sequences of human prion-like proteins. Additionally, it can find application in the in silico design of synthetic
prion-like proteins with tuned aggregation propensities for different purposes. AMYCO does not require previous
registration and is freely available to all users at: http://bioinf.uab.cat/amyco/.
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Background
Prions are proteins able to adopt multiple structural con-
formations from which at least one has self-propagating
properties [1]. Yeast prions are the best understood subset
of functional prions. A common feature of most yeast
prions is the presence of an intrinsically disordered and
low complexity prion domain (PrD), which is necessary
and sufficient for prion conversion and propagation. Pro-
teins bearing prion-like domains (PrLDs) sharing these
properties seem to exist in all kingdoms of life [2–6]. In
particular, around 1% of the human proteome has been
predicted to correspond to prion-like proteins [7]. This
human protein subset is enriched in nucleic acid-binding
proteins and involved in the formation of membraneless
compartments through highly dynamic liquid-liquid
demixing [7, 8]. A number of mutations in human PrLDs
have been shown to convert these liquid compartments
into solid aggregates, abolishing their dynamic nature and
leading to the onset of neurodegenerative disorders [8, 9].
The development of tools able to anticipate the impact of
such pathogenic amino acid changes is attracting increas-
ing interest.
The self-assembling properties of prion-like pro-
teins have been traditionally thought to rely on the
biased amino acid composition of their PrLDs [10].
Disease-linked mutations would enhance the
self-association of these domains, facilitating the
transition to amyloid-like states [11, 12]. We have
recently shown that the impact of point and multiple
mutations or deletions on the aggregation of the
model ALS-associated prion-like hnRNPA2 protein is
best predicted by a function that takes into account
both compositional features and amyloidogenic pro-
pensities [13]. Here we introduce the AMYCO (com-
bined AMYloid and Composition based prediction of
prion-like aggregation propensity) web server, which
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implements this approach to perform automated and
fast predictions on top of prion-like protein
sequences.
Implementation
AMYCO is written in Python and uses python2.7 as the
interpreter (Anaconda distribution). The web interface
has been build using html/css and inputs and outputs
are processed by a cgi written in perl. It all runs in a
CentOS 5 server with Apache 2.2.3 using Intel Xeon
‘Clovertown’ processors.
AMYCO pipeline
AMYCO evaluates the impact of mutations on the ag-
gregation propensity of PrLDs in prion-like proteins.
They can be single or multiple residues substitutions, as
well as deletions and insertions. It exploits the highly
significant correlation between the scores obtained from
Fig. 1 Correlation between AMYCO and pRANK predictions and the aggregation propensity of human hnRNPA2 prion-like protein variants. a
Graphic representation of the correlation between the mutants' AMYCO (a) and pRANK (b) scores and their ability to form prionic colonies (Ade
+) when expressed in yeast, a direct reporter of their aggregation propensity [13]
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a parameterized linear function, that balances the contri-
bution of both PrLDs composition and amyloid propen-
sity [13], and the intracellular aggregation of hnRNPA2
variants; the unique prion-like protein for which a large
set of mutations, both natural and artificial have been
experimentally validated (Fig. 1a). The contribution of
PrLDs amino acid composition to prion-like proteins
aggregation is calculated using the PAPA algorithm [10],
a program that exploits a scale of prion propensity
scores for natural amino acids derived from mutagenesis
experiments in the Sup35 yeast prion domain [14]. The
impact of amyloidogenic sequences within the PrLDs is
calculated with pWALTZ [12], a program specially
intended to identify short sequences of moderate amyl-
oid propensity able to nucleate the aggregation reaction,
as those found in yeast prion domains [15]. The outputs
of the two different programs are combined in a linear
manner, as described in detail in the Additional file 1.
The AMYCO web server is free and open to all users,
and no previous login or registration is required.
The home page of AMYCO displays three clickable
links in its upper margin: (i) a help page containing a
brief description of the method, the output explan-
ation and information on examples, (ii) references for
the methodology and the web application and (iii) a
contact e-mail. Immediately below two links allow to
switch between the Compare Sequences mode in
which multiple sequences can be compared to a refer-
ence one, and the Single Mutation mode in which all
possible mutations for a given protein residue are
evaluated. The adjacent “Example” button fills the in-
put text areas with the full-length sequences of wild
type (wt) human hnRNPA2 protein and its
aggregation-prone D290V mutant [16] for Compare
Sequences mode, or all its possible mutants for
position 290 for Single Mutation mode.
The input interface allows two working modes. In
Compare Sequences mode (default mode); the user
should introduce a reference sequence and the mutated
variants (one or several) in the left and right text boxes,
respectively; all in FASTA format. In the Single Mutation
mode, the user should introduce a single sequence as
well as the position to be scanned. Protein sequences
should be at least 60-residues long and only the 20
standard proteinogenic amino acids are allowed.
After submission, the output page will display a job
identification number along with the names of the input
sequences and the mutation position if applicable. The
algorithm will return the AMYCO score for each
sequence, together with a description of the mutations
impact of the overall aggregation propensity. In addition,
a graphical representation of the mutation/s effect will
be displayed (Fig. 2). We set two arbitrary thresholds of
low (< 0.45) and high (> 0.78) AMYCO scores to
visualize better the overall aggregation propensities of
the variants. hnRNPA2 mutants scoring < 0.45 were
shown to decrease or increase < 5 times the propensity
of the non-aggregating wild type protein, whereas,
mutants scoring > 0.78 increased its aggregation by > 50
times [17]. Therefore, mutations rendering an AMYCO
score < 0.45 are considered of low aggregation propen-
sity and labeled in blue. Mutations that increase the ag-
gregation propensity of the protein, but whose AMYCO
score is below 0.78 are labeled in red, whereas mutations
above this threshold are considered to be of high aggre-
gation propensity are labeled in red and bold. Sequences
might display AMYCO scores > 1.0, indicating that they
are predicted to be more aggregation-prone than the
Fig. 2 Graphical representation of the AMYCO score. AMYCO output representation of a low aggregation-prone (D290V Y283K), the wild type, the
natural pathogenic mutant D290V and a high aggregation-prone (D290V D276V) hnRNPA2 prion-like protein variants
Iglesias et al. BMC Bioinformatics           (2019) 20:24 Page 3 of 5
highest scoring hnRNPA2 variant used in the paramet-
rization of the prediction function. The output files can
be downloaded for further analyses, as a ZIP file con-
taining the resulting text explanation, a machine read-
able JSON file, the visualizations as a PNG file and
FASTA files with the introduced sequences and the
virtually generated mutants in Compare Sequences and
Single Mutation modes, respectively.
Results
Performance
pRANK is a novel multiple-instance machine learning
method aimed to predict prion propensity based on
amino acid composition alone [18]. We compared the
performance of AMYCO and pRANK web servers in
predicting the impact of mutations on human hnRNPA2
aggregation propensity (Fig. 1). AMYCO clearly outper-
forms pRANK (Table 1), an observation which is con-
sistent with the important influence that sequential
features exert on protein aggregation [19].
AMYCO was further assayed on known mutations
promoting the apparition of a de novo prion-like behav-
ior (Table 2). It was able to predict a large increase in
aggregation propensity for mutations that convert the
non-prionic PrLDs of PUF4, YLR177W, KC11 and
PDC2 yeast proteins into prionic when expressed in
yeast [20] (Table 2). Importantly, according to AMYCO,
five out of the eight variants were predicted to have ac-
quired a very high aggregation propensity. These vari-
ants are exactly the ones experimentally shown to
induce a prionic phenotype with basal protein levels,
without a need for overexpression [20] (Table 2).
Finally, AMYCO is able to predict an increase in ag-
gregation propensity for a series of disease-linked
mutations occurring in different human prion-like pro-
teins. In particular, mutations in hnRNPA1 associated to
ALS [16], mutations in hnRNP D0/AUF1 identified in
familiar cases of Crohn Disease [21] and mutations in
hnRNP DL causing limb-girdle muscular dystrophy 1G
[22] (Table 3). In contrast, natural variants of these pro-
teins bearing mutations in the PrLDs not associated to
clinical phenotypes [23] do not have any significant
Table 1 Performance of pRANK and AMYCO approaches in the
prediction of mutation impact upon the aggregation of the







Mean % error −7.08 −1.25
Standard Deviation (%) 37.71 12.19
SEM (%) 8.04 2.44
Coefficient of Determination 0.152 0.882
P-value (two tailed test) 0.468 < 1.00E-08
Rho (ρ) 0.334 0.929
The best performance according to each particular parameter is shown in
bold. Details on the calculation of the different statistic parameters are
provided in the Additional file 1
Table 2 AMYCO correctly predicts prion converting mutations
on yeast proteins













AMYCO correctly predicts mutations that induce prionic phenotypes.
Mutations predicted to increase and highly increase aggregation propensity
are shown in italics and bold, respectively. Variants that do not need
overexpression to generate a prionic phenotype in yeast are indicated with an
asterisk [20]
Table 3 AMYCO predicts disease-causing mutations on human
prion-like proteins







hnRNP DL wt 1.18
hnRNP DL D378H 1.26
hnRNP DL D378N 1.30
hnRNP D0 wt 1.13
hnRNP D0 F225 L 1.13
hnRNP D0 D319V 1.33
hnRNP D0 isoform-2 D300V 1.33
AMYCO identifies multisystem proteinopathy and ALS causing mutations on
hnRNPA1 [16], Crohn Disease causing mutations on both isoforms of hnRNP
D0/AUF1 [21] and limb-girdle muscular dystrophy 1G (LGMD1G) on hnRNP DL
[22] are shown in bold. Natural variants not associated to a clinical phenotype
are shown in italics
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impact in the polypeptides predicted aggregation
propensity.
Conclusion
AMYCO has been developed as a web application to as-
sess the impact of mutations on the aggregation propen-
sity of prion-like proteins, allowing a fast and accurate
evaluation of the effect of disease-associated mutations
in these polypeptides; as well as engineering novel vari-




Project home page: http://bioinf.uab.cat/amyco/.
Operating system(s): Platform independent.
Programming language: A computing core coded in
Python and a front end written in a combination of html
and perl cgi.
Other requirements: A web browser with a working
internet connection.
License: None.
Any restrictions to use by non-academics: None.
Additional file
Additional file 1: Dataset obtention and performance analysis. (PDF 219 kb)
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